Health systems

Cancer care continues to innovate and evolve at astounding speeds, presenting complex challenges to health systems that want to provide meaningful care for their patients.
A health care provider seated at a conference table with colleagues having a discussion.
Exact Sciences understands the business health systems run, and the challenges they face along the cancer care continuum. From risk to remission, we partner with health systems to provide full-spectrum cancer screening and tests that can help improve risk profiling, treatment plans, patient adherence, and outcomes.

Loading component...

Together, we can:

Optimize and automate workflows that support clinicians and staff

Address population health, equity, and quality goals

Provide personalized, best-in-class support for patients along their journey

Real-world experience

See how other health systems have successfully collaborated with Exact Sciences to improve cancer screening.

Tools that work on your terms to optimize cancer detection

Exact Sciences’ goal is to provide innovative solutions at speed and scale, in one comprehensive portfolio, backed by complete support. Our screening portfolio includes

  • The Cologuard Plus® test—The first and only FDA-approved stool DNA test that offers early stage detection of colorectal cancer (CRC) in average-risk patients aged 45+1
  • The Cancerguard® test—An innovative multi-cancer early detection (MCED) test that complements standard-of-care screening and can help detect multiple cancers with a simple blood draw2
Lab technician putting samples into a piece of equipment.
An Exact Sciences lab technician opening an OncoExTra test kit box.

Precision oncology: Testing for every stage of care

Exact Sciences’ Precision Oncology portfolio doesn't stop with a test's science. It also reflects the realities of the clinical setting and what providers can face when ordering tests and delivering results to patients.

Pairing comprehensive, world-class genomic tests like the Oncotype DX® test with a connected digital infrastructure

  • Helps to efficiently create a complete picture of each patient's unique cancer
  • Enables providers and their patients to focus on what matters most—the best way forward

We’re equipped to integrate solutions into your workflows, streamlining your genomic cancer testing and helping you match your patients with emerging personalized treatments.

ExactNexus™ technology platform: Streamlined and secure care

Our ExactNexus technology platform helps create a unified clinical experience within the Exact Sciences ecosystem to deliver our tests and seamlessly connect health systems, providers, payers, and patients.
ExactNexus by Exact Sciences.

Connect with us

Let’s discuss how we can support your health system’s cancer screening goals.

We're aligned with your priorities.

Industry partnerships with organizations like the ones listed below connect Exact Sciences directly to the evolving priorities of health system leaders, ensuring the solutions we develop are aligned with real-world clinical, operational, and strategic needs.
America College of Healthcare Executives for leaders who care.
Visit our corporate partner page at ACHE.org for our latest on-demand webinars, videos, case studies, and articles.
AMGA.
Visit our corporate partner page at AMGA.org for our latest webinars and other resources.

Important Information about the Cologuard products


Indications for Use

The Cologuard® and Cologuard Plus® tests are intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced precancerous lesions (APL) and should be followed by a colonoscopy. The Cologuard test and Cologuard Plus test are indicated to screen adults of either sex, 45 years or older, who are at average risk for CRC. These tests are not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Contraindications

The Cologuard products are not for high-risk individuals, including patients who have the following:

  • a personal history of colorectal cancer or precancerous colon polyps​
  • a positive result from another colorectal cancer screening method within that test's recommended screening interval​
  • have been diagnosed with a condition associated with high risk for colorectal cancer such as inflammatory bowel disease (IBD), chronic ulcerative colitis (UC), Crohn’s disease
  • have a first-degree family history of colorectal cancer, or certain hereditary syndromes

Patients should talk to a healthcare provider if any of these situations apply.


Warnings and Precautions

All positive results should be referred to colonoscopy.

The Cologuard products may produce false positive and false negative results. A false positive result occurs when a result is positive, even though a colonoscopy will not find CRC or APL. A false negative result occurs when a result is negative, even when a colonoscopy identifies APL or CRC.

A negative result does not guarantee the absence of colorectal cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Performance when used for repeat testing has not been established.

Refer to the Cologuard test Clinician Brochure or the Cologuard Plus test Clinician Brochure for additional information about the benefits and risks of using each version of the Cologuard product for CRC screening.

Rx only.